Cagrilintide

Phase 3Peptide

Cagrilintide is used to help people with type 2 diabetes control their blood sugar levels and lose weight by slowing down how quickly food moves through the stomach.[1] Cagrilintide is currently being investigated across 6 indications[3], with its most advanced program in Phase 3.[1]

Cagrilintide is one of 153 peptide programs targeting Cardiovascular Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

152

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

OverweightNot yet recruiting

Weight LossActive, not recruiting

ObesityRecruiting

Body WeightCompleted

Overweight Body Mass Index StatusActive, not recruiting

Cardiovascular DiseasePhase 3

Active, not recruiting

OverweightPhase 1

Not yet recruiting

Weight LossPhase 3

Active, not recruiting

ObesityPhase 3

Recruiting

Body WeightPhase 3

Completed

Overweight Body Mass Index StatusPreclinical

Active, not recruiting

Competition

Competitive Landscape

176 competitors in Obesity

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Phase 3

2 2

Cagrilintide

Novo Nordisk

Phase 3

9 3

NNC0487-0111

Novo Nordisk

Phase 3

11 4

Zenagamtide

Novo Nordisk

Phase 3

5 5

PF-08653944

Pfizer

Phase 3

6 6

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

1 7

Ribupatide

KKailera

Phase 3

3 8

Actemra

Roche

Preclinical

2 9

Avapro

Sanofi

Preclinical

1 10

Amidate

Pfizer

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Overweight

NCT07411560

Q2 2027

Phase 3Active, not recruiting

Obesity

NCT07220642

Phase 3Active, not recruiting

Obesity

NCT07220759

Q3 2027

Phase 3Recruiting

Obesity

NCT07745504

Q4 2027

Phase 3Active, not recruiting

Cardiovascular Disease

NCT05669755

Phase 1Recruiting

Obesity

NCT07607587

Clinical

Trials by Indication[1]

Obesity9 trials

A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06131437·809 enrolled

Tolerability of Cagrilintide in People With Obesity That Discontinued GLP-1-RA Therapies Due to Gastrointestinal Adverse Events: a Double-blinded Randomised Feasibility Study

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07607587·114 enrolled

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity and Type 2 Diabetes

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07220759·330 enrolled

Show 6 more trials

Efficacy, Safety and Pharmacokinetics of Cagrilintide s.c. 2.4 mg as Monotherapy and in Combination With Semaglutide s.c. 2.4 mg (CagriSema) Once Weekly for Weight Management in Chidren and Adolescents With Overweight or Obesity

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07253285·460 enrolled

Efficacy and Safety of Cagrilintide s.c. 2.4 Milligram (mg) in Combination With Semaglutide Subcutaneous (s.c). 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-weekly in Participants With Overweight or Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05567796·3,400 enrolled

The Role of the Amylin Analogue Cagrilintide in Bone Metabolism During Weight Loss in Postmenopausal Women With Obesity

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07010432·144 enrolled

A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07745504·285 enrolled

A Randomized, Placebo Controlled and Double-blinded Study Assessing the Safety, Tolerability, Pharmacokinetics, and Efficacy of Subcutaneous Administrations of NNC0174 1213 in Male Participants With Overweight or Obesity.

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06719011·178 enrolled

Efficacy and Safety of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT07220642·300 enrolled

Body Weight5 trials

A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05813925·331 enrolled

A Research Study to Look at How CagriSema Influences Food Intake, Appetite and Emptying of the Stomach in People With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06207877·62 enrolled

A Study of How CagriSema Works on Appetite in People With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06267092·164 enrolled

Show 2 more trials

A Research Study to See How Well CagriSema Helps People in China With Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05996848·300 enrolled

A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06388187·300 enrolled

Type 2 Diabetes5 trials

A Research Study to See How Well CagriSema Helps People With Type 2 Diabetes and Excess Body Weight Lose Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05394519·1,200 enrolled

Investigating How CagriSema, Semaglutide and Cagrilintide Regulate Insulin Effects in the Body of People With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06403761·158 enrolled

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 2.4 mg/2.4 mg s.c. Once Weekly Versus Tirzepatide 15 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06221969·1,024 enrolled

Show 2 more trials

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4 mg/2.4 mg and 1.0 mg/1.0 mg Once Weekly Versus Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Diet and Exercise

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06323174·189 enrolled

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06323161·274 enrolled

Overweight2 trials

A Research Study to Compare Blood Levels of Cagrilintide and Semaglutide After Combined Versus Separate Injections in People With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT04940078·40 enrolled

A Study Looking at How Weekly Injections of Two Hormones - GIP and Amylin - Affect Stomach-related Side Effects in People Who Are Overweight or Obese

Not yet recruiting· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT07411560·100 enrolled

Liver Disease1 trial

Effects of NNC0194-0499, Cagrilintide, and Semaglutide Alone or in Combinations on Liver Damage and Alcohol Use in People With Alcohol-related Liver Disease

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06409130·270 enrolled

9 more indications

Atorvastatin1 trial

A Study on How CagriSema Affects Levels of Atorvastatin and Warfarin in the Blood of Participants With Excess Body Weight

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT06289504·34 enrolled

Heart1 trial

A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05804162·107 enrolled

Single Dose1 trial

A Research Study Looking at How a Single Dose of the Medicine Cagrilintide Works in Participants With Reduced Liver Function and in Healthy Participants With Normal Liver Function and How Cagrilintide is Absorbed and Used by the Body

Completed· Novo Nordisk logo

Novo Nordisk·Phase 1·NCT05564104·32 enrolled

Weight loss1 trial

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06780449·400 enrolled

Diabetes Mellitus, Type 21 trial

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) 1.0 mg/1.0 mg s.c. Once Weekly Versus Tirzepatide 5 mg s.c. Once Weekly in Participants With Type 2 Diabetes Inadequately Controlled on Metformin, SGLT2 Inhibitor or Both

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06534411·1,023 enrolled

Chronic Kidney Disease1 trial

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema 2.4 mg/2.4 mg) Once Weekly Versus Semaglutide 2.4 mg, Cagrilintide 2.4 mg and Placebo in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity

Completed· Novo Nordisk logo

Novo Nordisk·Phase 2·NCT06131372·626 enrolled

Cardiovascular Disease1 trial

The Cardiovascular Safety and Efficacy of Cagrilintide 2.4 mg s.c. in Combination With Semaglutide 2.4 mg s.c. (CagriSema 2.4 mg/2.4 mg s.c.) Once-weekly in Participants With Established Cardiovascular Disease

Active, not recruiting· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT05669755·7,101 enrolled

Type 2 Diabetes Mellitus1 trial

Efficacy and Safety of Co-administered Cagrilintide and Semaglutide (CagriSema) s.c. in Doses 2.4/2.4 mg and 1.0/1.0 mg Once Weekly Versus Semaglutide 2.4 mg and 1.0 mg, Cagrilintide 2.4 mg and Placebo in Participants With Type 2 Diabetes Inadequately Controlled on Metformin With or Without an SGLT2 Inhibitor

Completed· Novo Nordisk logo

Novo Nordisk·Phase 3·NCT06065540·2,734 enrolled

Heart Failure1 trial

HELIOS-B: Patisiran in Heart Failure with ATTR-CM

Active, not recruiting· Alnylam Pharmaceuticals logo

Alnylam Pharmaceuticals·Phase 3·NCT04982575·655 enrolled

Sources

References

[1]
ClinicalTrials.gov — 31 trial records for Cagrilintide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cagrilintide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cagrilintide. EMBL-EBI & Wellcome Sanger Institute.
[4]
PubMed — 10 publications indexed for Cagrilintide. U.S. National Library of Medicine.
[5]
SEC EDGAR — Novo Nordisk company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Amylin Analog[2]
Modality: Peptide[2]
Highest Phase: Phase 3[1]
Company: Novo Nordisk

Key Publications[4]

From withdrawal to motivation: The feasibility, acceptability and early clinical benefits of adapted physical activity during inpatient alcohol withdrawal.

Addict Behav RepDec 1, 2026DOI: 10.1016/j.abrep.2026.100749

Treatment of spinal tuberculosis- Evolution in last 50 years.

J Clin Orthop TraumaDec 1, 2026DOI: 10.1016/j.jcot.2026.103623

Risk of infection in ocrelizumab-treated adults with multiple sclerosis aged 55 years and older: a retrospective cohort study.

Lancet Reg Health AmDec 1, 2026DOI: 10.1016/j.lana.2026.101640

Exploring Sexually Transmitted and Bloodborne Infection Rates in Florida After Implementation of Syringe Services Programs: A Quasi-Experimental Study.

AJPM FocusDec 1, 2026DOI: 10.1016/j.focus.2026.100536

Predictors of COVID-19 vaccination status among youth in eThekwini, South Africa: results from the AYAZAZI RIGHTS study.

Glob Health ActionDec 1, 2026DOI: 10.1080/16549716.2026.2737555

Characteristics of new and re-initiating antiretroviral therapy clients in Malawi: implications for client counseling in resource-constrained settings.

Glob Health ActionDec 1, 2026DOI: 10.1080/16549716.2026.2740360

Data-Driven Clustering of Secretory Bone and Inflammatory Markers to Subphenotype Patients Undergoing Hemodialysis.

Kidney Int RepNov 1, 2026DOI: 10.1016/j.ekir.2026.107019

A Self-Reinforcing Hydrogel Disrupting Osteoclast Sealing Zone for Bone Erosion Alleviation.

Adv Healthc MaterOct 6, 2026DOI: 10.1002/adhm.71808

Genetics-Informed Pharmacological Intervention in Gestational Diabetes Mellitus: Current Therapeutic Alignment, Emerging Targets and a Translational Roadmap.

Diabetes Obes MetabOct 6, 2026DOI: 10.1111/dom.71404

Association of trunk and lower limb muscle thickness with sedentary behavior in patients with chronic post-stroke hemiplegia.

J Phys Ther SciOct 1, 2026DOI: 10.1589/jpts.38.438

Cagrilintide

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q3 2027

Q4 2027

Trials by Indication[1]

Obesity9 trials

Body Weight5 trials

Type 2 Diabetes5 trials

Overweight2 trials

Liver Disease1 trial

Atorvastatin1 trial

Heart1 trial

Single Dose1 trial

Weight loss1 trial

Diabetes Mellitus, Type 21 trial

Chronic Kidney Disease1 trial

Cardiovascular Disease1 trial

Type 2 Diabetes Mellitus1 trial

Heart Failure1 trial

References

Drug Info

Quick Facts

Key Publications[4]

Related News